Low dose bendrofluazide (1.25 mg) effectively lowers blood pressure over 24 h: Results of a randomized, double-blind, placebo-controlled crossover study

• Published in: American journal of hypertension 1999-05, Vol.12 (5), p.528-531
• Main Authors: Wiggam, M.Ivan, Bell, Patrick M, Sheridan, Brian, Walmsley, Anona, Atkinson, A.Brew
• Format: Article
• Language: English
• Subjects: Aged; ambulatory blood pressure monitoring; Antihypertensive agents; Antihypertensive Agents - administration & dosage; bendrofluazide; Bendroflumethiazide - administration & dosage; Biological and medical sciences; Blood Pressure - drug effects; Blood Pressure Monitoring, Ambulatory; Cardiovascular system; Circadian Rhythm - physiology; Cross-Over Studies; Double-Blind Method; Follow-Up Studies; Humans; hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Medical sciences; Pharmacology. Drug treatments; Thiazide diuretics; Treatment Outcome
• ISSN: 0895-7061; 1879-1905
• DOI: 10.1016/S0895-7061(98)00268-4

Previous studies indicate that low dose bendrofluazide (1.25 mg/day) has no deleterious effect on insulin sensitivity in contrast to conventional doses. To evaluate the antihypertensive effect of 1.25 mg bendrofluazide across 24 h, we studied 12 subjects in a randomized, double blind, cross-over trial, comprising 8 weeks of either 1.25 mg/day bendrofluazide or placebo. Twenty-four-hour blood pressure averages were significantly lower after bendrofluazide compared with placebo (systolic 125 ± 4 v 136 ± 3 mm Hg, P < .005; diastolic: 78 ± 2 v 85 ± 2 mm Hg, P < .01). Trough:peak ratios were 0.67 ± 0.07 for systolic and 0.72 ± 0.15 for diastolic blood pressure reduction. In conclusion, 1.25 mg bendrofluazide daily produced a useful antihypertensive effect across the full 24-h period.